The selected 49 applications are from 33 companies. Out of these 33 companies, 13 are Micro, Small and Medium Enterprises (MSMEs) besides some newly incorporated entities
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
